Physician profile
Scott R Yoder
NPI 1770591539
$9,378.54
in general payments reported to CMS, 2019-2025
37 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $536 · 2021: $4,409 · 2022: $881 · 2023: $888 · 2024: $568 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,680.33 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $528.09 | 2019-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $479.56 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $364.66 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $325.13 | 2019-2024 | |
| Amgen INC. | $312.04 | 2019-2023 | Repatha |
| United Therapeutics Corporation | $288.14 | 2019-2024 | Orenitram, Tyvaso |
| Pfizer INC. | $210.51 | 2019-2024 | |
| Mylan Specialty L.P. | $176.00 | 2019-2023 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $174.44 | 2019-2024 | Farxiga, Tagrisso |
| Abiomed | $156.70 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $148.62 | 2021-2025 | Verquvo |
| Scpharmaceuticals INC. | $128.55 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.34 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.37 | 2019-2025 | Lifevest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $113.67 | 2019-2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $92.84 | 2019-2022 | |
| Edwards Lifesciences Corporation | $92.31 | 2019 | |
| Medtronic Vascular, INC. | $84.26 | 2019 | |
| Lundbeck LLC | $78.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $74.55 | 2019-2023 | Onpattro |
| Biosense Webster, INC. | $74.39 | 2022 | |
| Glaxosmithkline, LLC. | $69.73 | 2019-2021 | |
| Irhythm Technologies, INC. | $62.68 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $60.88 | 2022 | |
| Medtronic, INC. | $47.31 | 2021 | |
| Heartflow, INC. | $44.46 | 2021 | |
| Shire North American Group INC | $44.34 | 2019 | |
| Cvrx, INC. | $41.72 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $39.54 | 2019-2020 | |
| Amarin Pharma, INC. | $35.43 | 2019-2022 | |
| Daiichi Sankyo INC. | $29.33 | 2023 | Injectafer |
| Lantheus Medical Imaging, INC. | $18.80 | 2021 | |
| Philips North America LLC | $15.88 | 2023 | |
| Baxter Healthcare | $15.40 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $14.20 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.